Tamoxifen 10 mg
10 mg · 100 tablets · Tamoxifen 10 mg is a SERM gold standard for anti-estrogenic and testosterone-boosting studies — ideal for gynecomastia, fertility, and HPG-axis recovery research with long receptor occupancy and strong oral PK profile.
€ 29.00
Beskrivelse
Tamoxifen 10 mg
Merkevare: Magnus Pharmaceuticals
Innhold: 100 tablets | 10 mg per tablet
Pris: €29
Manufactured in: Europe
🧪 Produktoversikt
Tamoxifen 10 mg delivers a high-purity selective estrogen receptor modulator (SERM) used extensively in both endocrine and androgen-focused research. By binding to ER-α/β receptors and blocking estrogen-mediated feedback on the hypothalamic–pituitary–gonadal (HPG) axis, tamoxifen promotes a cascade increase in LH, FSH, and endogenous testosterone in male models.
In female models, it remains the gold-standard anti-estrogen for ER-positive tumor protocols. Its high oral bioavailability (~100%) and long half-life (4–11 days for parent, up to 70 hours for active metabolite endoxifen) support once-daily use in long-range studies, including PCT, fertility, gynecomastia reversal, and hormone-modulation assays.
✅ Viktige forskningsresultater
HPG-axis stimulation:
10–20 mg/day for 3 months doubled serum testosterone in hypogonadal males [PMC]
Gynecomastia control:
Clinical data show significant breast tissue regression in AAS-using males on 10–20 mg/day
Anti-estrogen benchmark:
First-line SERM for ER+ breast cancer research and comparative estrogen-blocking trials [NCBI]
Pharmacokinetics:
~100% oral bioavailability; 4–11 day half-life (parent), 50–70 hours (endoxifen metabolite) [Wikipedia]
Storage & stability:
Film-coated tablets stable ≤25 °C with 36-month shelf-life — ideal for long-term protocols [PubChem, PubMed]
🧬 Suggested Laboratory Applications
-
HPG-axis and testosterone recovery models
-
Gynecomastia reversal and estrogenic side-effect prevention
-
SERM benchmarking in ER-positive breast-cancer assays
-
Post-cycle therapy research for anabolic models
-
Hormone-modulation pharmacokinetics
📊 Tekniske spesifikasjoner
| Felt | Data |
|---|---|
| Kjemisk navn | Tamoxifen (base); supplied as Tamoxifen Citrate |
| Kjemisk formel | C<sub>26</sub>H<sub>29</sub>NO (base) |
| Synonymer | Nolvadex; TMX; 4-(1-dimethylaminoethoxy)-diphenyl-1-ethenyl-phenol |
| Molekylvekt | 371.5 g/mol (base); 563.6 g/mol (citrate) |
| CAS-nummer | 10540-29-1 (base); 54965-24-1 (citrate) |
| Half-life | Parent: 4–11 days · Endoxifen: 50–70 hours |
| Detection Window | Long-acting — detectable for several weeks |
| Documented Benefits | ↑ LH/FSH, ↑ testosterone, ↓ gynecomastia, SERM gold standard |
| Main Risks | Hot-flushes, ↓ bone density, cataract risk, thrombo-embolism, lipid shifts |
| Total aktiv forbindelse | 1,000 mg tamoxifen base per carton (10 mg × 100 tablets) |
| Shelf-life | 36 måneder (produsentens spesifikasjoner) |
❄️ PubChem-Supported Research Insights
-
Blocks estrogen feedback to HPG axis → ↑ endogenous testosterone
-
Used clinically in both male infertility and female ER+ oncology
-
Demonstrated ability to reverse steroid-induced gynecomastia
-
Maintains receptor suppression up to 6 weeks post-use
-
Oral form preferred over injectable SERMs for logistical ease
⚠️ Dokumenterte forskningsbivirkninger
-
Hot-flushes, fatigue, and temporary visual disturbances
-
Lipid profile changes (↑ LDL / ↓ HDL) with long-term use
-
Thrombo-embolic events in susceptible models
-
Cataract formation risk at extended exposure
-
Reduced bone-mineral density (BMD) with prolonged protocols
🧯 Håndtering og etterlevelse
Kun til forskningsbruk — Not for human or veterinary use
Lagre på 15-25°C, protect from light and moisture
Kjøpet bekreftes qualified researcher status
Listed on WADA Prohibited List S4 (Hormone Modulators) — any exposure may trigger positive test
Det er ingen anmeldelser ennå.
